DeepIntent Cora

DeepIntent Cora is an agentic healthcare-marketing platform launched September 10, 2026. It is designed to move pharma marketers from market intelligence and natural-language analysis into audience creation, forecasting, omnichannel planning and activation inside collaborative human-and-AI workspaces.¹

DeepIntent says Cora uses purpose-built agents to interrogate healthcare data, build patient and HCP audiences, generate plans and move them toward activation. The launch describes cross-channel planning beyond programmatic media, including VideoAmp-powered linear-TV planning and forecasting, plus real-time signals from campaigns, competitors, clinical developments and market conditions.¹ Cora builds on the company's Helix data/cloud layer and existing healthcare advertising infrastructure.¹²

No exact public Cora list price was verified. Access is currently tied to DeepIntent clients and the open beta, which materially limits price transparency and broad accessibility compared with self-serve marketing software.¹

Cora is available to DeepIntent clients as an open beta, not a mature generally established product. DeepIntent reports a closed-beta survey of 275 customers in which 95% said workflows were drastically faster and planning cycles fell by at least 50%, but those figures are vendor-reported and are not treated as independent efficacy evidence.¹ Independent launch coverage confirms the product architecture and positioning, including multiple agents spanning planning and audience strategy, but does not provide hands-on performance testing.³

Cora operates in healthcare marketing, where audience selection and health-adjacent data make privacy and governance material. DeepIntent's broader platform publishes a platform privacy policy, describes HIPAA/NAI-compliant and privacy-safe infrastructure, maintains a Data HealthChecks program for third-party data vendors, and describes governance around sensitive data sourcing, consent and opt-in practices.²⁴⁵ Helix AI is presented as HIPAA-compliant and backed by HIPAA-grade governance.² These controls support a positive trust assessment, but AiToolMap has not independently tested Cora's data flows, agent actions or compliance controls. The product is a marketing platform, not a clinical decision system, and the review does not infer medical efficacy.

The active 50-source AiToolMap evidence panel was searched source by source. Forty-seven sources returned no current exact-product substantive evidence; Bloomberg, CNET and The New York Times were inaccessible through the available access path and were excluded rather than inferred. No eligible exact-product numeric external rating is therefore incorporated.